Monopar Therapeutics Inc (MNPR)
R&D Expense Growth
76051.28%
Fiscal year · Period ending:
MNPR R&D Expense Growth
Latest reported76051.28%period ending
Latest reported76051.28%period ending
MNPR FY R&D Growth (YoY) (0.00% → 76051.28%)
Latest values, visible window
High-resolution chart · PNG
MNPR r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 76,051.2814% | |
| 132.2417% | |
| -26.2317% | |
| 16.916% | |
| 59.7267% | |
| 106.5106% | |
| 10.9649% | |
| 89.6679% | |
| 233.6195% | |
| 176.2472% | |
| 0% |